Table 2.
Quality assessment of eligible studies.
| References | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Sum score |
|---|---|---|---|---|---|---|---|---|---|---|
| Optale et al. (2010) | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Man et al. (2012) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Hughes et al. (2014) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Wang and Lv (2016) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Schwenk et al. (2016) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Delbroek et al. (2017) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Hwang and Lee (2017) | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 7 |
| Hwang and Park (2018) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Hu et al. (2018) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Choi and Lee (2019) | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 5 |
| Amjad et al. (2018) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Liao Y. Y. et al. (2019) | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Liao Y. et al. (2019) | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Yang et al. (2019) | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 7 |
| Park et al. (2019) | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
Indicate notes as following: Item 1, eligibility criteria; Item 2, randomization; Item 3, concealed allocation; Item 4, similar baseline; Item 5, blinding of assessors; Item 6, more than 85% retention; Item 7, missing data management (intent-to-treat analysis); Item 8, between-group comparison; Item 9, point measure and measures of variability; 1, explicitly described and present in details; 0, absent, inadequately described, or unclear.